Alain BECK
Senior Director, Biologics CMC and Developability Pierre Fabre
Dr Alain Beck is Senior Director, Biologics CMC and Developability (Pierre Fabre), co-founder and Associate Editor of mAbs journal (2009) and chairman of MabDesign SAB (2014). He is or was involved in +12 clinical stage biologics programs including dalotuzumab (Merck), telisotuzumab (telisotuzumab vedotin (Emrelis) and adizutecan/ cMet (AbbVie)), h515H7 mAb, lonigutamab (Acelyrin) and lonigutamab ugodotin ADC/ IGF1R, W0180 Vista IO mAb (PF), VERT-002/ cMet (Vertical Bio) and efsudenermin alpha (Esperare Foundation). He is author/ co-author of +270 publications (h-index: 77; +20,200 citations). He has contributed to +300 scientific meetings worldwide as chairman, invited keynote speaker, panellist, moderator, advisor, and/or organizer. He was the winner of 6th WADC (2019). He is member of the MAB Working Party (PhEur) and involved in scientific workshops with ANSM, EU, EMA, FDA, NIST, USP and WHO.
Seminars
- XDCs are not a single modality but a family of highly diverse conjugate formats
- The combination of different targeting moieties, linker chemistries, payload classes, and conjugation strategies generates substantial molecular heterogeneity that cannot be captured by traditional biologics characterisation approaches alone
- Sharing case-studies of XDC attributes and development requiring integrated, orthogonal characterisation strategies that combine advanced analytics with functional assays
